Wild About Sprouts® Celebrates World Food Safety Day with Breakthrough Cold-Grown® Technology That Redefines Safety and Nutrition
SCOTTSDALE, Ariz., June 6, 2025 /PRNewswire/ — In honor of World Food Safety Day June 7, Wild About Sprouts® is shining a spotlight on its revolutionary Cold-Grown® process—an all-natural, patented innovation that has redefined food safety standards in the sprouting industry. With over 25 million containers sold pathogen-free and never part of any recall over its 8+ years, Wild About Sprouts is the only national sprout brand in the U.S., now proudly available in over 7,000 grocery stores across the country.
Sprouts are among the most powerful, studied, and nutrient-dense superfoods on the planet. Yet for decades, their potential has been limited by persistent food safety concerns. Wild About Sprouts has solved that problem. Its Cold-Grown® process eliminates the risk of dangerous pathogens without the use of pesticides, herbicides, or chemical intervention, and uses 95% less water than traditional growing systems—making it one of the most sustainable solutions in fresh food today.
'At Wild About Sprouts, food safety isn't a feature—it's the foundation,' said Barry Didato, CEO of Rä Foods, parent company of Wild About Sprouts. 'Our patented Cold-Grown® method is changing the way America eats—combining breakthrough safety with unmatched nutrition, delivering sprouts that contain up to 100 times more antioxidants, vitamins, and minerals than fully grown vegetables. Backed by over 2,000 studies, sprouts—especially broccoli sprouts—are rich in sulforaphane, a proven compound that supports the body's natural detox pathways, helps fight cancer, reduces inflammation, and shows promise in managing conditions like autism, diabetes, and neurodegenerative disease.'
Observed every year on June 7, World Food Safety Day highlights the importance of safe, accessible food for all. Wild About Sprouts is proud to lead this charge—proving that innovation can make clean, nutrient-packed, fresh foods not just possible, but scalable.
'Wild About Sprouts has not only innovated with its Cold-Grown® technology—they've demonstrated an uncompromising commitment to public health,' said Dr. Darin Detwiler, Food Safety Advocate, Professor and Author of Food Safety: Past, Present, and Predictions. 'In an era when consumers demand both transparency and accountability, this company offers a clear model of how science and responsibility can align to create safer, more sustainable food systems. As we recognize World Food Safety Day, this kind of leadership is precisely what our food system needs to move from reaction to prevention.'
Whether tossed in a salad, layered on a sandwich, or blended into smoothies, Wild About Sprouts products offer an easy and delicious way to boost everyday nutrition—safely.
For more information, visit www.wildaboutsprouts.com or follow us on Instagram at @wild_about_sprouts. Wild About Sprouts is available at major retailers including Kroger, Walmart, Whole Foods Market, Sprouts Farmers Market, Albertsons, and many more.
About Wild About Sprouts®Founded in 2016 and based in Scottsdale, Arizona, Wild About Sprouts is transforming the sprout industry with its science-backed, Cold-Grown® technology. As part of Rä Foods, a family office dedicated to better-for-you innovations, Wild About Sprouts is on a mission to deliver safe, delicious, nutrient-dense foods that Make America Healthy Again—one sprout at a time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
Counterfeit and Refurbished Transducers Pose Serious Safety Risks
HONG KONG SAR & MACAU SAR - Media OutReach Newswire - 30 June 2025 - Merz Aesthetics®, the world's largest dedicated medical aesthetics business for more than 115 years, leads the industry shift with Ultherapy PRIME®, the latest innovation in hyper-personalized, non-invasive skin lifting., which have earned the trust and support of medical aesthetics professionals and consumers in Hong Kong and Macau. Recently, the emergence of counterfeit and refurbished transducers in the local markets pose serious potential risks to treatment results and patients' safety. Merz Aesthetics® Hong Kong urges consumers to verify the authenticity of Ultherapy® products and seek treatments exclusively at authorized clinics. Merz Aesthetics® Hong Kong will launch the Ultherapy® Authenticity Verification Reward Program this August — making it easy for consumers to verify the Systems and transducers, reinforcing confidence and safety in every treatment. Trusted Technology, Proven Results — Beware of Counterfeit Transducers Ultherapy® and its latest innovation, Ultherapy PRIME® (collectively 'Systems'), are manufactured in the United States and remain the only US FDA cleared non-invasive micro-focused ultrasound skin lifting treatment with real-time visualization.. Ultherapy® DeepSEE® transducers are available in 4.5mm, 3.0mm, and 1.5mm depths to target different layers of the skin. The real-time imaging allows practitioners to visualize skin structure and tissue layers during treatment, ensuring that energy is precisely delivered to the intended depth of the skin for safe and effective results. Each Ultherapy® DeepSEE® transducer is designed to deliver a designated 2,400 dosage lines and cannot be recharged or refurbished once depleted. The recent emergence of counterfeit or refurbished transducers in the market has raised serious concerns over treatment results and patients' safety. Inaccurate energy delivery into the skin will compromise lifting results and create extremely high risks, potentially leading to burns. The use of counterfeit or refurbished transducers can also impair the Systems, potentially leading to unpredictable outcomes that may cause harm to patients. Authentic Transducers Are Traceable — Counterfeit Unknown Every Ulthera® DeepSEE® transducers carries a unique serial number and QR code, allowing it to be traced back to the purchasing clinic. Counterfeit or refurbished transducers often fail QR verification, raising questions about their origin and posing significant safety risks. In addition, every authentic transducer has a specified shelf-life which is12 months from the date of manufacture. Expired transducers should not be used, as they may result in unpredictable outcomes which can possibly harm or injure the patients because there is no clinical evidence to support the use of such expired transducers. Choose Only Authorized Ultherapy® Clinics Our official Ultherapy® website ( regularly updates the list of clinics and medical aesthetic centers that use authentic Systems and transducers. Each authorized provider receives official certificates for in-clinic display. Merz Aesthetics® urges consumers to choose authentic Ultherapy® treatments from officially authorized clinics and aesthetic centers to ensure that only certified Systems and transducers are used. Products obtained through unauthorized or parallel import channels may not comply with the manufacturer's prescribed storage and handling standards, potentially compromising safety and efficacy. 3-Step Verification Program Launches This August To help consumers easily identify authentic Systems and transducers, Merz Aesthetics® Hong Kong is launching the Ultherapy® Authenticity Verification Reward Program in August 2025. With just three simple steps, consumers can authenticate products and enjoy a special reward: 1. Scan the QR code on the System to verify authenticity. Counterfeit machines typically lack valid QR verification. 2. Take a photo of the QR code on the transducer and upload it to the official website for instant verification. 3. Successfully complete both verifications to receive a HK$100 Häagen-Dazs coupon as your reward (limited quantities, available in Hong Kong only). Report Suspected Counterfeit or Refurbished Devices Merz Aesthetics® Hong Kong will continue to take enforcement action against the sale or use of counterfeit version of the Ultherapy® and Ultherapy PRIME® systems, as well as unauthorized, refurbished, or counterfeit transducers. The company also warns against any unauthorized modifications or repairs of the Systems. Only authorized representatives and service centers, certified by the manufacturer, are properly trained and qualified to inspect, repair, or replace components of the Systems. Merz Aesthetics® Hong Kong believes that the patients' well-being and treatments safety are core values shared with its network of professional medical partners. We urge both providers and consumers to report any suspected use of counterfeit systems, counterfeit transducers, or refurbished transducers. Consumers are encouraged to consult the official Ultherapy® website ( for a list of authorized clinics before treatment. With the launch of the Ultherapy® Authenticity Verification Reward Program this August 2025, they can also complete a simple verification process to confirm that both the Systems and transducers are authentic ensuring every session is safe, effective, and provides piece of mind.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ — Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent's transformative vision for the future of oncology. 'Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies,' said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. 'We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innovation of next-generation IO and next-generation ADC. Our recent presence at the 2025 ASCO with eight oral presentations highlights the strength and global competitiveness of our R&D. But this is only the beginning. With a clear vision to advance at least five pipeline assets into MRCT Phase 3 by 2030, we are committed to delivering innovative, high-quality, and accessible cancer treatments to patients worldwide.' Dual Innovation to Unlock the Future of Oncology: Next-gen IO + Next-gen ADC At the core of Innovent's oncology strategy lies the dual engines of next-generation immunotherapy (IO) and next-generation antibody-drug conjugates (ADC), supported by deep insights in cancer biology and differentiated technology platforms. 'We are harnessing deep cancer biology insights, advanced antibody and protein engineering, and differentiated ADC linker-payload technologies to develop broader-spectrum, more potent, and less toxic therapies aimed at transforming the oncology treatment paradigm,' said Dr. Zhou Hui, SVP of Innovent Oncology R&D. 'Our strategy is designed to target some of the toughest challenges in cancer care, including drug resistance, cold tumors, and improve the efficacy of current IO treatment, while bringing new hope to patients worldwide.' Global R&D Roadmap: a Clear, Stepwise Development Strategy Innovent's pipeline is guided by a rational, phased IO+ADC combination strategy designed to address tumor heterogeneity and immune escape, evolving through three stages: Next-gen IO + Chemotherapy: to redefine the IO cornerstone Next-gen IO + mAb-ADC / bispecific ADC: to cover expansive tumor types and treatment lines Next-gen IO + Dual-Payload ADC (dpADC): to unlock full potential of IO+ ADC synergy, and reshape cancer treatment Currently its oncology pipeline features nearly 10 next-generation molecules in global development, with multi-regional trials actively underway in the U.S., EU, and Asia. The company also continues to invest in global R&D infrastructure, supported by R&D hubs in Shanghai and San Francisco and antibody and ADC manufacturing capacity exceeding 140,000L. Innovent is rapidly expanding its global innovation footprint, with a 2030 goal to advance at least five pipeline assets into global MRCT Phase 3 trials. Key potential candidates includes: IBI343: innovative CLDN18.2 ADC with site-specific conjugation and a TOPO1 inhibitor payload, demonstrating significant survival benefits in both GC and PDAC IBI363: PD-1/IL-2α-bias fusion protein as next-gen IO to redefine cancer treatment and expand the boundaries of IO responsiveness IBI3009: DLL3 ADC in collaboration with Roche IBI3003: tri-specific T-cell engager targeting BCMA/GPRC5D/CD3 for multiple myeloma IBI3001: EGFR/B7H3 ADC with two synergetic targets covering multiple potential indications IBI3020: CEACAM5 dual-payload ADC as globally the first to enter clinical phase IBI363: Next-Gen IO Redefining Cancer Immunotherapy IBI363 is a global first-in-class PD-1/IL-2α-bias fusion protein, featuring a differentiated molecular design and a dual immune activation mechanism. Emerging clinical data strongly support its mechanism of action in reinvigorating and expanding tumor-specific T cells (TSTs). At ASCO 2025, IBI363 demonstrated breakthrough potential in three hard-to-treat tumor types, with a long tailing effect in prolonged survival benefits: Immune-resistant NSCLC (squamous & Adeno): boosted response rate and extended PFS reflects strong immune activation; median overall survival (mOS) up to 17.5 months in 1.5 mg dose cohorts, 12-month OS rate exceeding 70% for 3 mg dose cohorts, and benefit observed even in PD-L1 low expressers Later-line CRC (3L+): mOS of 16.1 months in monotherapy and only 17.8% OS events occurred in combination with bevacizumab with 9.4 months follow-up, outperforming historical benchmarks Immune-resistant melanoma (mucosal/acral subtypes): confirmed overall response rate (cORR) 23%, median duration of response (mDoR) 14 months, and median OS 14.7 months, showing unprecedented positive response and a long-lasting immunologic tailing effect With two Breakthrough Therapy Designations from the NMPA CDE, two Fast Track Designations from the FDA, IBI363 is advancing rapidly toward registrational development. The first head-to-head trial vs. pembrolizumab in mucosal and acral melanoma was initiated. Meanwhile, IBI363 is in preparation for registrational trails in IO-treated squamous NSCLC, and third-line MSS colorectal cancer. Additional trails for first-line and other solid tumors also under exploration in ongoing PoC studies. High-Potency, Low-toxicity ADC Platforms Synergizing with IO for Broad Indication Coverage Innovent is rapidly advancing its next-gen ADC pipeline, including: IBI343 (CLDN18.2 ADC): first in PDAC to demonstrate long-term survival benefits (mOS 12.1 months in 2L) IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumors IBI3020 (CEACAM5 dual payload ADC): designed for high efficacy and low toxicity in treatment-resistant tumors These programs leverage proprietary payloads and linkers, optimized for lower toxicity and high potency, and are poised to synergize with Innovent's IO agents to address broader and deeper indications. Innovent Academy: R&D Engine to Drive Global Innovation Innovent Academy is the company's discovery engine for driving global innovation. The Academy continues to expand its platforms in IO, ADC, T-cell engagers, and cytokines, firmly establishing its leadership in next-gen oncology discovery and translational science to generate 6–8 novel molecules per year. Specifically, for next-gen IO and next-gen ADC dual upgradation, Innovent Academy focuses on: diversified antitumor mechanisms to integrate TME modulation and optimize IO efficacy; dual targeting approaches to overcome tumor heterogeneity and drug resistance. This framework allows Innovent to systematically escalate efficacy and broaden tumor applicability, laying the foundation for first-in-class and best-in-class combination regimens for cancer treatments. Catalyzing China's Role in Global Oncology Innovation Leading oncology KOLs and principal investigators (PIs) delivered keynote speeches, reflecting on a pivotal moment for China's biotech industry. They emphasized that China's innovation, which is driven by rising translational capabilities, expanding global talent pools, and patient-centric trial execution, has entered a 'Deepseek' moment, one where Chinese-discovered drugs can lead global standards, not just follow them. 'What we're witnessing is a profound shift,' said one keynote speaker. 'Innovent's next-generation IO programs like IBI363, with a clear global-first design, and ADC platforms targeting previously untreatable populations, show that Chinese biotech is poised to influence—not just participate in—the next global oncology paradigm.' The enthusiastic response from investors and KOLs underscores growing confidence in China-originated oncology innovation and reaffirms Innovent's position as it enters a new era of global innovation with a vision to become a global premier biopharmaceutical leader. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications (NDA) under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
The Star
3 hours ago
- The Star
Matcha: the Japanese tea taking over the world
The word matcha means "ground tea" in Japanese and comes in the form of a vivid green powder that is whisked with hot water and can be added to milk to make a matcha latte. — Photo: Frederic J. BROWN/AFP Matcha is the new drink of choice at hip cafes worldwide, but Japanese producers are struggling to keep up with soaring demand for the powdered green tea. Here's what you need to know about the drink beloved of weekend treat-seekers and "wellness" influencers: What is matcha? The word matcha means "ground tea" in Japanese and comes in the form of a vivid, green powder that is whisked with hot water and can be added to milk to make a matcha latte. Green tea was introduced to Japan from China in the early ninth century, and was first used for medicinal purposes. Matcha came much later, in 16th century Kyoto – part of the tea ceremony tradition developed by tea master Sen no Rikyu. Today, there are different grades of matcha quality, from "ceremonial" to "culinary" types used in baking. How is it produced? Matcha is made from leaves called "tencha", which are grown in the shade in the final weeks before their harvest to concentrate the flavour, colour and nutrients. This "requires the construction of a complex structure with poles and a roof to filter the light", explained Masahiro Okutomi, a tea producer in Sayama, northwest of Tokyo. Tencha leaves, rich in chlorophyll and L-theanine, a compound known for its relaxing effects, are hand-picked and deveined, then steamed, dried and ground between two stone mills to produce an ultra-fine powder. It can take up to an hour to produce just 40 grams (1.4 ounces) of matcha – making the powder on average twice as expensive to produce as standard green tea leaves. What are its benefits? Many drink matcha for its rich grass-like taste, but others are drawn to the drink's nutritional properties. It is rich in antioxidants, and can aid concentration because of its caffeine content: one cup contains on average 48 milligrams, slightly less than a drip coffee but nearly twice as much as a standardly brewed green tea. "Matcha is often seen as being good for your health," said Shigehito Nishikida, manager of Tokyo tea shop Jugetsudo. "But people are also attracted to the Japanese culture around tea: the ritual, the time taken, the aesthetics," he said. Why is it so popular? Japan produced 4,176 tonnes of matcha in 2023 – a huge increase from the 1,430 tonnes in 2012. More than half of the powder is exported, according to the agriculture ministry, mostly to the United States, Southeast Asia, Europe, Australia and the Middle East. Millions of videos on TikTok, Instagram and YouTube demonstrate how to make photogenic matcha drinks or choose a traditional "chasen" bamboo whisk. "I feel like Gen Z really drove this enthusiasm for matcha, and they heavily relied on social media to do so," Stevie Youssef, a 31-year-old marketing professional, told AFP at a matcha bar in Los Angeles. Matcha can also be used in cooking, extending its appeal to others aside from tea lovers. "Some customers simply enjoy drinking it, others like preparing it themselves. And of course, many buy it as a gift – Japanese matcha is always appreciated," said Jugetsudo's Nishikida. – AFP
